Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Sep 11, 2024 3:45pm
111 Views
Post# 36219135

RE:RE:RE:RE:RE:RE:Andrey Omelchak - BNN - TOP PICK

RE:RE:RE:RE:RE:RE:Andrey Omelchak - BNN - TOP PICKI also think that Goodman has other concerns other than maximizing return for himself. Although he made a lot of money from Paladin, it doesn't seem that it was the way he wanted to go out, especially considering he started Knight the very next day. 

Barring something outside his control like a takeover attempt, I don't see them taking this private. They can win along with their long-term shareholders together, which I think is more aligned with Goodman as a person (although maybe I'm naive). As long as they keep performing, the share price will rise. The story will get out there as seen from yesterday. You can't keep this "hidden gem" quiet forever and I don't see Goodman screwing his shareholders who've backed him from the beginning at the moment this stock hits an inflection point higher.

GUD is still way too cheap at $6, but it looks like that gap is starting to close.


<< Previous
Bullboard Posts
Next >>